Based on 1 analysts giving stock ratings to Werewolf Therapeutics Inc in the past month.
In the current month, HOWL has received 0 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. HOWL average Analyst price target in the last month is 5.500.
Based on analysts' estimates, HOWL EPS is projected to reach -0.170 in FY2026Q4, following reported EPS of -0.200 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.20, while Werewolf Therapeutics IncHOWL's earnings per share (EPS) for the previous quarter was USD 0.08. EPS for the next quarter is expected at USD -0.17.